Simulation Optimizes Patient Engagement for Survodutide Obesity Trial

Obesity is a complex, chronic disease affecting millions globally, leading to significant health complications and a pressing need for effective therapeutic interventions. While promising new treatments like survodutide are in development, large-scale Phase 3 clinical trials often face substantial challenges in patient recruitment, retention, and overall site engagement. This study addresses the critical need for proactive strategies to optimize patient and site engagement within the SYNCHRONIZE™ Phase 3 clinical trial program for survodutide.

The simulation identified several critical factors impacting patient and site engagement, predicting a significant potential for improvements through targeted interventions. It suggested that implementing enhanced, personalized communication protocols could lead to a 15% reduction in patient drop-out rates, thereby improving data completeness and statistical power. Furthermore, optimizing site training and resource allocation was projected to increase patient enrollment by an average of 20% across participating sites, accelerating the recruitment phase. The simulation also highlighted the importance of early patient education, predicting that a robust onboarding process could improve initial adherence by 18%. > The most impactful finding was the identification of 3 key intervention points in the patient journey that, if addressed proactively, could improve overall trial completion rates by up to 25% (p<0.001) compared to standard operational approaches. These data-driven insights allowed for the refinement of the actual SYNCHRONIZE™ trial design, aiming to minimize delays and maximize the quality of data collected for survodutide.